Bio-Rad also disclosed during an earnings call that it acquired an undisclosed company that will expand its genomic reagents product portfolio.
The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
The test is for monitoring treatment response in chronic myeloid leukemia and uses a new Droplet Digital PCR instrument.
The kit, which was launched today, leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6.
The project builds on a collaboration between Bio-Rad and Genetic Analysis using the GA-map clinical test for gut dysbiosis.
The infringement relates to US patents held by the University of Chicago and exclusively licensed to Bio-Rad.
The contract covers Bio-Rad's iQ-Check RT-PCR pathogen detection test kits, which cover pathogens including Salmonella spp. and Listeria monocytogenes.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.